Lonza Group stock steadies as investors weigh 2024 earnings reset and 2025 guidance

Lonza Group stock reflects an earnings reset after the CDMO adjusted its 2024 outlook and set new 2025 guidance, while investors assess margins, CapEx discipline, and large biologics contracts on the SIX Swiss Exchange.

Lonza Group stock trades on the SIX Swiss Exchange under ISIN CH0013841017 as investors digest an earnings reset following the companys updated 2024 outlook and new 2025 guidance, alongside the impact of major biologics contracts on revenue visibility. According to Lonzas 2023 annual results published on 24 January 2024, the company reported group sales of CHF 6.7 billion for fiscal 2023, an increase from CHF 6.2 billion in 2022 driven mainly by its Biologics and Small Molecules businesses. In the same report, Lonza highlighted an accelerated investment phase and a recalibration of margins that continue to frame the discussion around the stock in 2024.

Revenue up from CHF 6.2 billion

In its 2023 annual report, Lonza stated that group sales reached CHF 6.7 billion in 2023 compared with CHF 6.2 billion in 2022, reflecting growth of roughly CHF 0.5 billion year on year, primarily from commercial and late-stage development projects in Biologics. The company also reported a 2023 CORE EBITDA of around CHF 2.0 billion, corresponding to a CORE EBITDA margin in the low thirties percent range, down from a mid-thirties margin level in 2022 as capacity expansions and inflation weighed on profitability. According to the same disclosure, Lonza confirmed that its mid term ambition remains to deliver sustained double digit sales growth, supported by the continued expansion of its large scale biologics manufacturing network.

Alongside the backward looking figures, Lonza provided guidance that has effectively reset investor expectations for the current planning period. For 2024, the company guided for group sales growth in the mid single digit percentage range at constant exchange rates and a CORE EBITDA margin in the high twenties to around thirty percent, lower than the margin achieved in 2023 due to portfolio changes and ramp up of new assets. At a capital markets day and subsequent investor communications, Lonza also outlined a 2025 ambition of returning CORE EBITDA margin toward approximately thirty two percent on the back of better utilization of large scale facilities and a more focused project mix. This guidance corridor now acts as a key reference point when market participants value Lonza Group stock against global CDMO peers.

Guidance and margins drive valuation debate

Lonzas updated outlook has become central to how investors compare the company with other contract development and manufacturing organizations. According to its published guidance materials for the 2024 to 2026 period, the company expects capital expenditure to normalize toward roughly twenty to twenty five percent of sales after a peak investment phase that saw CapEx near or above that range in 2022 and 2023. The gradual reduction in CapEx intensity, combined with higher utilization of biologics lines, is intended to support a step up in free cash flow generation from 2025 onward. At the same time, Lonza has emphasized that portfolio measures, including the divestment of non core assets, are designed to support a more predictable earnings profile.

From an earnings quality perspective, the 2023 annual report shows that Lonza generated CORE EBIT of around CHF 1.5 billion, translating into a CORE EBIT margin in the low twenties percent range. This compares with a slightly higher margin level in 2022, underlining that the margin reset was already visible before the 2024 guidance cut. Management has indicated that a combination of new customer contracts, including large scale biologics supply agreements, and efficiency programs should enable margins to improve from the trough forecast for 2024. For investors, the quantified margin trajectory between the high twenties percent in 2024 and low thirties percent ambition for 2025 is now a central factor in assessing the upside and downside risk in Lonza Group stock.

Biologics manufacturing underpins growth

A large share of Lonzas revenue growth continues to come from its Biologics division, which supplies drug substance manufacturing services for monoclonal antibodies and other complex biologics. According to its 2023 segment disclosure, Biologics generated several billion Swiss francs of sales and grew faster than the group average, supported by commercial volumes and late stage clinical projects. The company has invested heavily in large scale mammalian manufacturing campuses, which are intended to support multi year contracts with major biopharmaceutical customers.

In parallel, Lonza is working to balance growth with profitability in its Small Molecules and Cell and Gene divisions. Segment data for 2023 show that some of these activities experienced lower margins due to ramp up costs and project timing effects. The strategic rationale of retaining a diversified CDMO platform is that it allows Lonza to offer integrated services along the drug development value chain while maintaining exposure to high growth areas such as cell and gene technologies. For shareholders, this mix means that long term value creation depends not only on topline growth but also on disciplined project selection and execution across different technology platforms.

Lonza Group stock on SIX Swiss Exchange

Lonza Group shares are listed on the SIX Swiss Exchange in Swiss francs and are included in major Swiss equity indices, which anchors the stock in both domestic and international portfolios. Exchange and market data providers report that, as of recent trading sessions in 2024, Lonza carries a multibillion CHF equity valuation, reflecting its role as one of the largest global CDMOs. The market capitalization figure fluctuates with the share price, but the companys scale means that even modest changes in earnings expectations can move billions of Swiss francs in implied equity value.

Recent share price performance has broadly mirrored the shifting outlook for earnings and margins following the guidance reset. Around late January 2024, after the publication of full year 2023 results and the updated outlook, Lonza shares traded significantly below their 2021 peak but above the lows reached during previous episodes of sector risk aversion. For many investors, the key reference points now are the implied valuation multiples when using the 2024 guided CORE EBITDA margin in the high twenties percent and the 2025 ambition of around thirty two percent, as these metrics help to position Lonza Group stock relative to other global CDMO and specialty pharma service peers.

Fact box: Lonza Group key data

Lonza Group at a glance

• Company: Lonza Group Ltd.
• ISIN: CH0013841017
• Ticker: SIX: LONN
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Health Care / Life Sciences Tools and Services
• Index membership: SMI and other Swiss equity indices